Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled Phase III Study, to Evaluate the Efficacy, Safety and Tolerability of Eltrombopag Olamine (SB-497115-GR), a Thrombopoietin Receptor Agonist, Administered for 6 Months as Oral Tablets Once Daily in Adult Subjects With Previously Treated Chronic ITP.
Brief Summary: The rationale for this Phase III study is to evaluate the 6 month safety and efficacy of eltrombopag in the treatment of previously treated subjects with chronic ITP. The starting dose of eltrombopag, 50 mg, once daily was selected based upon the observed efficacy, safety and pharmacokinetics in a dose-finding Study (TRA100773). This Phase III study is a randomized, double-blind, placebo-controlled, Phase III study, to evaluate efficacy, safety and tolerability of eltrombopag, initially administered as 50 mg oral tablets once daily for six months in adult subjects with previously treated chronic ITP. Subjects will be randomized 2:1, eltrombopag to placebo, and will be stratified based upon splenectomy status, use of ITP medication at baseline and baseline platelet count less than or equal to 15,000/µL. Subjects will receive study medication for 6 months, during which the dose of study medication may be adjusted based upon individual platelet counts. In addition, subjects may taper off concomitant ITP medications and may receive any rescue treatments as dictated by local standard of care. After discontinuation of study medication, subjects will complete follow-up visits at weeks 1, 2, 4 and months 3 and 6.


Options:
A: Intervention Type: DRUG; Name: SB497115; Assigned to Arm(s): N/A
B: Arm Label: Treatment arm plus standard of care; Type: EXPERIMENTAL; Interventions: Drug: eltrombopag | Arm Label: placebo plus standard of care; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: eltrombopag; Assigned to Arm(s): Treatment arm plus standard of care | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo plus standard of care
C: Arm Label: Part A: Romiplostim 0.2 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 0.5 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 1.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 3 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 6 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part A: Romiplostim 10 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part B: Romiplostim 1.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Romiplostim 3.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Arm Label: Part B: Romiplostim 6.0 µg/kg; Type: EXPERIMENTAL; Interventions: Drug: Romiplostim | Intervention Type: DRUG; Name: Romiplostim; Assigned to Arm(s): Part A: Romiplostim 0.2 µg/kg, Part A: Romiplostim 0.5 µg/kg, Part A: Romiplostim 1.0 µg/kg, Part A: Romiplostim 10 µg/kg, Part A: Romiplostim 3 µg/kg, Part A: Romiplostim 6 µg/kg, Part B: Romiplostim 1.0 µg/kg, Part B: Romiplostim 3.0 µg/kg, Part B: Romiplostim 6.0 µg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part B: Placebo
D: Arm Label: Romiplostim; Type: EXPERIMENTAL; Interventions: Biological: Romiplostim | Intervention Type: BIOLOGICAL; Name: Romiplostim; Assigned to Arm(s): Romiplostim

Answer: B